Aytu BioPharma, Inc.
Aytu BioPharma, Inc.
Your view on AYTU
Overview
What the company does, where it operates, and who runs it.
About Aytu BioPharma, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Joshua R. Disbrow
- Headquarters
- 373 Inverness Parkway, Englewood, CO, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Joshua R. Disbrow
- Headquarters
- 373 Inverness Parkway, Englewood, CO, US
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.
The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.
It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Aytu BioPharma, Inc. from FRC's valuation model, read against the market price. AYTU last traded at $1.82; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aytu BioPharma, Inc.. Starting points for Aytu BioPharma, Inc.: EPS -$1.16, beta 0.27 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Aytu BioPharma, Inc.. Aytu BioPharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aytu BioPharma, Inc.. Trailing twelve-month EPS for Aytu BioPharma, Inc. stands at -$1.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy5
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | -$0.20 | -$0.13 | -$0.62 | $0.27 |
| Low estimate | -$0.21 | -$0.13 | -$0.64 | $0.26 |
| High estimate | -$0.20 | -$0.13 | -$0.59 | $0.28 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$1.051 | -$0.53 | -$1.161 | — |
| Growth | — | +76.1% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | $15.28M | $18.36M | $67.91M | $86.91M |
| Low estimate | $15.14M | $18.19M | $65.19M | $83.43M |
| High estimate | $15.49M | $18.62M | $69.72M | $89.22M |
| No. of analysts | 2 | 1 | 2 | 2 |
| Year-ago revenue | $15.16M | $12.41M | $57.57M | — |
| Growth | +0.8% | +48.0% | +18.0% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 17, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aytu BioPharma, Inc.. Aytu BioPharma, Inc. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALURAllurion Technologies Inc.Medical - Devices$11M
- ANLAdlai Nortye Ltd. American Depositary SharesBiotechnology$532M
- BFRIBiofrontera Inc.Medical - Pharmaceuticals$8M
- GOVXGeoVax Labs, Inc.Biotechnology$850,325
- NVNOenVVeno Medical CorporationMedical - Devices$4M
More Drug Manufacturers - Specialty & Generic companies
- PBFFFPlanet Based Foods Global Inc.OTC$825,651
- PCLO.VPharmaCielo Ltd.TSXV
- PCLOFPharmaCielo Ltd.OTC$7M
- PCRXPacira BioSciences, Inc.NASDAQ$1.5B
- PCYNProcyon CorporationOTC$2M
ETFs holding Aytu BioPharma, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- DCORDimensional - US Core Equity 1 ETF$43.9B in assets0.00%
- DFACDimensional - US Core Equity 2 ETF$85.6B in assets0.00%
- DFASDimensional - US Small Cap ETF$33.7B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
Largest holders first, then the funds most concentrated in AYTU.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Aytu BioPharma, Inc., and how their positions are changing. At a $19.8M market value, institutional positions materially move Aytu BioPharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Aytu BioPharma, Inc. executives and directors. Shares of Aytu BioPharma, Inc. have traded between $0.95 and $2.82 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aytu BioPharma, Inc.. Coverage tracks Aytu BioPharma, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aytu BioPharma, Inc.